Coherus BioSciences (NASDAQ:CHRS) Bolsa

Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Coherus BioSciences Inc

<a href="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view" title="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view">https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view</a>

Biotech

News

Contracts

General

CHRS

Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

Coherus Biosciences Announced Final Data From Its Phase 2 Open Label Clinical Trial Evaluating Casdozokitug In Combination With Atezolizumab And Bevacizumab (Bev) In Treatment Naïve Patients With Unresectable Locally Advanced Or Metastatic Hepatocellular Carcinoma

Guidance

Coherus Biosciences Sees FY24 Prelim. Net Revenues $255M-$260M

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.&nbsp;(("Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a poster presentation at the upcoming 2025 ASCO GI Annual Meeting, being held January 23-25, 2025, in San Fransisco, CA.

Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and raises the price target from $4 to $6.

Baird Maintains Outperform on Coherus BioSciences, Raises Price Target to $6

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) shares moved upwards by 67.4% to $67.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.5 billion. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares rose 48.9% to $2.04. The company's market cap stands at $235.0 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 22.54% to $1.25. The market value of their outstanding shares is at $89.1 million. </li>
<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) shares rose 21.47% to $9.9. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 19.29% to $1.36. The company's market cap stands at $8.1 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) stock rose 18.76% to $7.09. The company's market cap stands at $231.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock decreased by 27.7% to $6.07 during Tuesday's pre-market session. The market value of their outstanding shares is at $205.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares decreased by 24.36% to $2.89. The market value of their outstanding shares is at $27.2 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock decreased by 16.51% to $2.8. The company's market cap stands at $5.0 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 14.73% to $0.81. The market value of their outstanding shares is at $3.4 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) shares fell 13.78% to $2.63. The company's market cap stands at $68.6 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares fell 12.31% to $0.74. The company's market cap stands at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CTOR

GELS

JANX

KDLY

NSPR

PEPG

PPBT

REVB

STSS

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Tuesday,&nbsp;Coherus BioSciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42286067/coherus-announces-agreement-to-divest-udenyca-franchise-for-up-to-558-million-to-intas-pharmaceuti" rel="noreferrer noopener">up to $558.4 million</a>.
The deal consideration includes an upfront payment of $483.4 million, to be adjusted for inventory at the close, and $75 million in potential net sales milestone payments.
Coherus plans to use a portion of the transaction proceeds to fully repay the company&#8217;s $230 million in existing convertible notes due April 2026 and $49.1 million to buy out certain royalty obligations related to Udenyca.
&#8220;The proposed divestiture of Udenyca represents the successful execution of our strategy to focus R&amp;D and commercial resources on Coherus&#8217; innovative immuno-oncology portfolio and to strengthen our financial position,&#8221; said Denny Lanfear, Coherus chairman and chief executive officer.
The proposed transaction is expected to close by the end of Q1 2025.
Coherus intends to strengthen and sharpen its focus on advancing its immuno-oncology portfolio in combination with Loqtorzi, a next-generation, differentiated PD-1 marketed in the U.S. in two indications.
Additional partnerships evaluating Loqtorzi with other cancer agents are planned for 2025.
The company plans to initiate a Phase 2 trial of casdozokitug/toripalimab/bevacizumab in first-line (1L) hepatocellular carcinoma (HCC) in Q4 2024, with final data from Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC in Q1 2025, and data from its Phase 1 study of casdozokitug/toripalimab in second to fourth line (2-4L) non-small cell lung cancer (NSCLC) in 1H 2025.
Coherus plans to:
<ul>
<li>Report Phase 1 monotherapy biopsy data and CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) in 1H 2025.</li>
<li>Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L head and neck squamous cell carcinoma in Q1 2025, with a first data readout expected in Q2 2026.</li>
<li>Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025, with a first data readout expected in Q2 2026.</li>
</ul>
Earlier this year, Coherus BioSciences divested its Cimerli ophthalmology franchise to&nbsp;Sandoz Group AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>)&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>)&nbsp;for $170 million plus an&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36716756/why-is-cancer-immunotherapy-focused-coherus-biosciences-stock-trading-higher-today" rel="noreferrer noopener">additional amount for inventory</a>.
Price Action: CHRS stock is up 41.6% at $1.94 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42272645/merus-licenses-us-commercialization-rights-for-cancer-potential-zenocutuzumab-analyst-highlight-merus-pipeline" target="_blank" rel="noreferrer noopener">Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus&#8217; Pipeline</a></li>
</ul>
Photo: Shutterstock

Health Care

Trading Ideas

SDZNY

SDZXF

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

WIIM

Coherus Biosciences shares are trading higher after the company announced an agreement to divest its Udenyca franchise for $558.4 million.

<ul>
<li>This includes an upfront payment of $483.4 million, to be adjusted for inventory at close, and $75.0 million in potential net sales milestone payments. Coherus plans to use a portion of the transaction proceeds to fully repay the entirety of the Company's $230.0 million in existing convertible notes due April 2026 and $49.1 million to buy-out certain royalty obligations related to UDENYCA.</li>
<li>Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor.</li>
<li>Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody.</li>
<li>Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026</li>
</ul>

Coherus Biosciences Has Agreed To Divest Udenyca (Pegfilgrastim) Franchise To Intas Pharmaceuticals For Up To $558.4M

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $8 to $4.

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $4

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q3 financial results.

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.12) by 91.67 percent. The company reported quarterly sales of $70.77 million which beat the analyst consensus estimate of $59.23 million by 19.49 percent. This is a 5.09 percent decrease over sales of $74.57 million the same period last year.

Earnings

Earnings Beats

Reported November 6: Coherus BioSciences Q3 2024 Adj EPS $(0.01) Beats $(0.12) Estimate, Sales $70.77M Beat $59.23M Estimate

<h3>Gainers</h3>
<ul>
<li>Celularity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELU#NASDAQ">CELU</a>) shares moved upwards by 36.8% to $1.98 during Thursday's regular session. The market value of their outstanding shares is at $43.6 million. As per the news, the Q2 earnings report came out today. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares moved upwards by 31.25% to $0.95. The market value of their outstanding shares is at $109.4 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares increased by 30.76% to $12.03. The market value of their outstanding shares is at $630.3 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock increased by 29.17% to $0.71. The market value of their outstanding shares is at $10.6 million. </li>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock rose 23.03% to $0.08. The market value of their outstanding shares is at $4.0 million. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) shares rose 19.61% to $5.0. The company's market cap stands at $151.1 million. As per the press release, Q3 earnings came out yesterday. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Xilio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) shares fell 28.7% to $0.92 during Thursday's regular session. The company's market cap stands at $40.4 million. </li>
<li>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares fell 24.69% to $18.06. The company's market cap stands at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) shares declined by 19.54% to $4.49. The market value of their outstanding shares is at $296.0 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Axogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXGN#NASDAQ">AXGN</a>) shares decreased by 17.75% to $12.61. The company's market cap stands at $552.6 million. The company's, Q3 earnings came out today. </li>
<li>Harvard Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares fell 17.56% to $2.33. The market value of their outstanding shares is at $101.3 million. As per the press release, Q3 earnings came out today. </li>
<li>Clover Health Investments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLOV#NASDAQ">CLOV</a>) shares decreased by 16.41% to $3.64. The market value of their outstanding shares is at $1.8 billion. As per the press release, Q3 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXGN

CELU

CLOV

ENSC

HBIO

PSNL

XRAY

12 Health Care Stocks Moving In Thursday's Intraday Session

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $12 price target.

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Coherus Biosciences shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $4 to $1.5.

UBS analyst Ashwani Verma downgrades Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) from Buy to Neutral and lowers the price target from $4 to $1.5.

Downgrades

UBS Downgrades Coherus BioSciences to Neutral, Lowers Price Target to $1.5

Coherus BioSciences shares are trading higher after the company reported better-than-expected Q2 financial results.

Press Releases

Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction

Coherus to Report Second Quarter 2024 Financial Results on August 8, 2024

Coherus BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Coherus to Report Third Quarter 2024 Financial Results on November 6, 2024

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million  to Intas Pharmaceuticals Ltd.

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Comments

Coherus BioSciences

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL